Sodium-glucose cotransporter-2 inhibitors and angiotensin receptor-neprilysin inhibitors (ARNIs) have since been demonstrated (47) to improve chronic heart failure prognosis (7, 46). The gene discussed is SLC5A2; the disease is congestive heart failure.